DITROPAN TABLETS 5MG 5 MG — DIN 01924761
OXYBUTYNIN CHLORIDE : 5 MG · JANSSEN INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DITROPAN TABLETS 5MG?
DITROPAN TABLETS 5MG 5 MG contains OXYBUTYNIN CHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 01924761, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Aug-2006. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is DITROPAN TABLETS 5MG used for?
Relief of symptoms associated with voiding in patients with uninhibited neurogenic bladder and reflex neurogenic bladder (urgency, frequency, leakage, urge incontinence, dysuria).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Oxybutynin cost around the world?
Oxybutynin is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 40 | USD███.██ |
| South Africa | single exit price | 4 | 8 | ZAR███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Romania | max producer price | 1 | 3 | RON███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
62 pack listings across 18 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Oxybutynin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Oxybutynin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
19 holders have a Canadian DIN containing Oxybutynin, across 35 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 3 | 3 | PMS-OXYBUTYNIN | Sourceable in Canada |
| APOTEX INC | 4 | 1 | APO-OXYBUTYNIN, OXYBUTYNIN, OXYBUTYNIN SYRUP | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 1 | NTP-OXYBUTYNIN, TEVA-OXYBUTYNIN | Sourceable in Canada |
| JANSSEN INC | 5 | 0 | DITROPAN SYRUP 1MG/ML, DITROPAN TABLETS 5MG, DITROPAN XL | No marketed DIN |
| PATRIOT A DIVISION OF JANSSEN INC | 3 | 0 | PAT-OXYBUTYNIN CHLORIDE ER | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-OXYBUTYNIN | No marketed DIN |
| LABORATOIRE RIVA INC. | 2 | 0 | RIVA-OXYBUTYNIN | No marketed DIN |
| PURDUE PHARMA | 2 | 0 | UROMAX | No marketed DIN |
| ALLERGAN INC | 1 | 0 | OXYTROL | No marketed DIN |
| SANIS HEALTH INC | 1 | 0 | OXYBUTYNIN | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 1 | 0 | OXYBUTYN - 5MG | No marketed DIN |
| WATSON LABORATORIES INC | 1 | 0 | GELNIQUE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: Bottles of 100 and 500. Syrup: Bottles of 473 mL. |
| Storage | Store at 15° to 30°C in tight, light-resistant containers. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Oxybutynin |
|---|---|
| ATC code | G04BD04 |
| AHFS class | 86:12.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01924761 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1924761 |
| Brand name | DITROPAN TABLETS 5MG |
| Generic / active ingredient | OXYBUTYNIN CHLORIDE : 5 MG |
| Market authorization holder | JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | G04BD04 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G04BD |
| Current status | CANCELLED POST MARKET |
| Status date | 04-Aug-2006 |
| Original market date | 1993-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 5 mg 2-3 times/day (max 4 times/day). Children >5: 5 mg 2 times/day (max 3 times/day). Start at lowest dose in elderly/debilitated.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Urinary retention, gastric retention, severe decreased GI motility, uncontrolled narrow-angle glaucoma, hypersensitivity to oxybutynin or any component.
Warnings and precautions
May cause heat prostration in high temperatures. May produce drowsiness or blurred vision; caution with machinery. May aggravate CHD, CHF, arrhythmias, hypertension, and hyperthyroidism.
Is Oxybutynin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by SANIS HEALTH INC, last seen 04 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 35 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXYBUTYNIN | 5 MG | TABLET | APOTEX INC | MARKETED | 02163543 |
| PMS-OXYBUTYNIN | 2.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02240549 |
| PMS-OXYBUTYNIN | 5 MG / 5 ML | SYRUP | PHARMASCIENCE INC | MARKETED | 02223376 |
| PMS-OXYBUTYNIN | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02240550 |
| TEVA-OXYBUTYNIN | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02230394 |
| ALBERT OXYBUTYNIN | 5 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | 02220067 |
| APO-OXYBUTYNIN | 1 MG | SYRUP | APOTEX INC | DORMANT | 02231089 |
| AVA-OXYBUTYNIN | 5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | 02363917 |
| DITROPAN SYRUP 1MG/ML | 1 MG | SYRUP | JANSSEN INC | CANCELLED POST MARKET | 01924753 |
| DITROPAN XL | 5 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | CANCELLED POST MARKET | 02243960 |
2 · Same class — other molecules in ATC G04BD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Solifenacin | ACH-SOLIFENACIN SUCCINATE · ACT SOLIFENACIN · APO-SOLIFENACIN · AURO-SOLIFENACIN · +15 more | 42 | 24 | Yes |
| Tolterodine | ACH-TOLTERODINE TARTRATE EXTENDED RELEASE · APO-TOLTERODINE · DETROL · DETROL LA · +9 more | 26 | 14 | Yes |
| Fesoterodine | ACH-FESOTERODINE · APO-FESOTERODINE · SANDOZ FESOTERODINE FUMARATE · TOVIAZ | 8 | 6 | Yes |
| Darifenacin | APO-DARIFENACIN · ENABLEX · JAMP DARIFENACIN | 6 | 6 | Yes |
| Oxybutynin | ALBERT OXYBUTYNIN · APO-OXYBUTYNIN · AVA-OXYBUTYNIN · DITROPAN SYRUP 1MG/ML · +18 more | 35 | 5 | Yes |
| Propiverine | MICTORYL · MICTORYL PEDIATRIC | 3 | 3 | Yes |
| Urinary Antispasmodics | MYRBETRIQ | 2 | 2 | Yes |
| Trospium | ACCEL-TROSPIUM · JAMP TROSPIUM · MAR-TROSPIUM · SANCTURA XR · +1 more | 5 | 1 | Yes |
| Flavoxate | APO-FLAVOXATE · FLAVOXATE · PMS-FLAVOXATE · URISPAS TAB 200MG | 5 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G04B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G04BE | Alprostadil · Sildenafil · Tadalafil · Vardenafil · Yohimbin | 269 | 123 |
| G04BX | Dimethyl Sulfoxide · Phenazopyridine | 8 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DITROPAN TABLETS 5MG called?
The same molecule, Oxybutynin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ditropan | Latin | Australia, South Africa |
| Lenditro | Latin | South Africa |
| Oxytrol | Latin | Australia |
| Sandoz Oxybutynin | Latin | South Africa |
| DITROPAN TABLETTA | Latin | Hungary |
| Syferid | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.